Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy

Nicoletta Burighel, Silvia Ghezzi, Silvia Nozza, Paola Del Bianco, Adriano Lazzarin, Giuseppe Tambussi, Guido Poli, Anita De Rossi

Research output: Contribution to journalArticlepeer-review

Abstract

Interleukin-2 (IL-2) increases circulating CD4+ lymphocytes in patients infected with human immunodeficiency virus-1. We studied Epstein-Barr virus (EBV) dynamics in 40 patients treated with antiretroviral therapy (ART) plus different IL-2 regimens. EBV-DNA tended to increase in both peripheral blood cells and plasma after continous infusion followed by intermittent subcutaneous high-dose IL-2, while EBV-DNA decreased in cells (p=0.0078) and disappeared in plasma after intermittent subcutaneous low-dose IL-2. Over 12 months, the dynamics of EBV differed between the two groups both in cells (p=0.0184) and plasma (p=0.0114). Thus, as a function of dose, IL-2 therapy may significantly affect the dynamics of EBV infection.

Original languageEnglish
Pages (from-to)244-247
Number of pages4
JournalHaematologica
Volume91
Issue number2
Publication statusPublished - Feb 2006

Keywords

  • ART
  • EBV
  • HIV-1
  • IL-2

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy'. Together they form a unique fingerprint.

Cite this